期刊文献+

氯吡格雷对阿司匹林抵抗的影响及其与他汀类药物的相互作用 被引量:9

在线阅读 下载PDF
导出
摘要 目的比较氯吡格雷联用不同种类的他汀类药物时血小板聚集率的差别,揭示其对氯吡格雷的抗血小板作用是否存在影响,明确氯吡格雷对阿司匹林抵抗的影响。方法将70例急性冠脉综合征(ACS)病人分为两组,阿司匹林组30例,入院后3d内口服阿司匹林300mg/d,后改为100mg/d至两周;联合用药组40例,阿司匹林服用如前,同时加用氯吡格雷75mg/d。于两周时采静脉血,应用比浊法分别测定二磷酸腺苷(ADP)和花生四烯酸(AA)诱导的血小板聚集率。又将联合用药组随机分为细胞色素氧化酶(CYP)3A4代谢的他汀组(A组,服阿托伐他汀10mg^40mg或辛伐他汀40mg或洛伐他汀40mg)和非CYP3A4代谢的他汀组(B组,服氟伐他汀80mg或普伐他汀20mg)各20例,两周时采静脉血测定血小板聚集率如前(仅观察ADP诱导的血小板聚集率)。结果联合用药组与阿司匹林组相比,两种不同诱导剂诱导的血小板平均聚集率均明显下降(P<0.05或P<0.01),其中以ADP诱导的血小板平均聚集率下降更显著,联合用药组阿司匹林抵抗(AR)与阿司匹林半抵抗(ASR)总发生率较单用阿司匹林组明显为低(P<0.05);CYP3A4代谢的他汀与非CYP3A4代谢的他汀组相比较,在与氯吡格雷联用时,对氯吡格雷抗血小板作用影响无统计学意义(P>0.05)。结论联用氯吡格雷可明显减少阿司匹林抵抗,从而减少不良心血管事件的发生。
出处 《中西医结合心脑血管病杂志》 2007年第12期1190-1192,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献10

  • 1Antithrobolic Trialst Collaboration. Collabotive meta-analysis of ran- domized trial of antiplatelet therpy for prevetion of 'death, myocardial infarction and stroke in high risk patients[J]. BMJ, 2002,324:71-86.
  • 2Gurn PA, Kottke MK, Poggio ED, et al. Profile and prevalence of asprin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001,88:230-235.
  • 3Weber AA, Przytulski B, Sehanz A, et al. Towards a definition of asprin resistance: A typological approach [J]. Plates, 2002,13 : 37 - 40.
  • 4Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-1 and prostaglandin E symptomatic atherosclerotic plaque as a basis of prostaglandin E (2) dependent plaque instability [J]. Circulation, 2001,104: 921-927.
  • 5Eikdboom JW, Hirsh J, Weitz JI, et al. Asprin resistant thrombox- ane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events [J]. Circulation, 2002,105:1650-1655.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to asprin in patients with acute coronary syndromes without ST-segment elevation [J]. NEJM, 2001,345 : 494 - 502.
  • 7Mehtau SR, Yusuf S, Oeers RJ, et al. Effects of pretreatment with clopidogrel and asprin followed by longterm therapy in patients under-going percutaneous coronary intervention: The PCI-CURE study [J]. Lancet, 2001,348:521-527.
  • 8Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders nong patients with stable angnia pectoris scheduled for elective stent placement[J]. Throm Haemost, 2003,89 : 783-787.
  • 9Lau WC, Waskell, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction[J]. Circulation, 2003,107(1) :32 - 37.
  • 10Saw J,Steinhubl SR,Berger PB,et al.Lack of adverse clopidogrel-ator-vastatin clinical interaction from secondary analysis of a randomized,placebo-controlled clopidogrel trial[J].Circulation,2003,108:921-924.

同被引文献87

引证文献9

二级引证文献155

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部